PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
November 12, 2025RespirationOpen Access

Drug-induced interstitial lung disease in lung cancer patients

View Full Paper
Ask AI
Bookmark
Share

Authors

GVGilles VanhandsaemeKVKarolien ViskensVBValerie Van Ballaer

Discussion

Loading...

Member takes

Overview

Review highlights risk factors and diagnostic approaches for managing pulmonary toxicity in lung cancer patients.

Key Points

  • To discuss the incidence, risk factors, clinical presentations, and management of drug-induced interstitial lung disease in lung cancer patients.
  • Review of literature on drug-induced interstitial lung disease (D-ILD) in lung cancer patients
  • Assessment of clinical, laboratory, imaging findings
  • Exploration of multidisciplinary approaches for management
  • Identified diverse presentations of D-ILD in lung cancer patients
  • Emphasized the importance of differential diagnosis and high level of suspicion
  • Recommended multidisciplinary engagement for managing D-ILD

Cite This Study

Vanhandsaeme et al. (2025) studied this question.

synapsesocial.com/papers/69252e83c0ce034ddc355a7chttps://doi.org/10.1159/000548862
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The Evaluation of the Oncologic Patient for Drug-Induced Pneumonitis2025
  2. 2Incidence and Clinical Characteristics of Drug-Induced Lung Disease Among Chemotherapy Recipients2024
  3. 3Incidence and prognostic factors in severe drug-induced interstitial lung disease caused by antineoplastic drug therapy in the real world2022 · 34 citations
  4. 4Lung Cancer and Interstitial Lung Diseases2024 · 7 citations
  5. 5Interstitial lung disease in patients enrolled in early-phase clinical trials: the ILDE study2024 · 2 citations